MabpharmHKSE:02181 38 FCF Margin % is -0.51% as of Dec. 2025. GuruFocus rates HKSE:02181 with a GF Score™ of 38/100 and a GF Value™ of HK$1.96 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 948 Biotechnology companies, Mabpharm ranks better than 72.15% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mabpharm's Free Cash Flow for the
six
months ended in Dec. 2025 was HK$-2.1 Mil. Mabpharm's Revenue for the
six
months ended in Dec. 2025 was HK$410.9 Mil. Therefore, Mabpharm's FCF Margin % for the quarter that ended in Dec. 2025 was -0.51%.
The historical rank and industry rank for Mabpharm's FCF Margin % or its related term are showing as below:
HKSE:02181'
s FCF Margin % Range Over the Past 10 Years
Min: -420.04 Med: -24.62 Max: 44
Current: -3.57
During the past 9 years, the highest FCF Margin % of Mabpharm was 44.00%. The lowest was -420.04%. And the median was -24.62%.
HKSE:02181's FCF Margin % is ranked better than 72.15% of 948
companies
in the Biotechnology industry
Industry Median: -81.28
vs HKSE:02181: -3.57
Mabpharm FCF Margin % Related Terms
Mabpharm FCF Margin % Historical Data
* Premium members only.
The historical data trend for Mabpharm's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02181 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Mabpharm's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabpharm FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabpharm's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Mabpharm's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabpharm (HKSE:02181) has a FCF Margin % of -0.51% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mabpharm and its competitors. According to the industry distribution chart, Mabpharm ranks #264 out of 948 companies in the Biotechnology industry, placing it in the top 27.8%.
Is Mabpharm's FCF Margin % too high?
Mabpharm's current FCF Margin % is -0.51%. Based on the distribution chart, Mabpharm ranks #264 out of 948 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mabpharm has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mabpharm's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mabpharm ranks #264 out of 948 companies for FCF Margin %. This puts Mabpharm in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mabpharm and its competitors. Mabpharm's current FCF Margin % is -0.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabpharm stock overvalued right now?
Based on GuruFocus' analysis, Mabpharm (HKSE:02181) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.96, compared to a current price of HK$0.40 — trading 79.8% below its estimated fair value. The current FCF Margin % is -0.51%. Mabpharm's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Mabpharm (HKSE:02181), the current FCF Margin % is -0.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mabpharm (HKSE:02181) Overvalued in 2026?
Based on GuruFocus' analysis, Mabpharm stock appears to be undervalued.
The current stock price of HK$0.40 is trading 79.8% below its estimated GF Value™ of HK$1.96.
GuruFocus considers Mabpharm to be Possible Value Trap.
Key valuation signals for HKSE:02181:
FCF Margin %: -0.51%
GF Value™: HK$1.96 vs. price of HK$0.40 (79.8% below fair value)
No single metric tells the full story. See the HKSE:02181 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
38GF Score
Get the complete analysis for HKSE:02181
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02181 has been successfully added to your 
